

F.Y.

2023-2024

AUDIT REPORT

RAYZON BIOCARE PRIVATE LIMITED

BLOCK NO-105,
NR HARIYA TALAV B/H ARON PIPES,
VILLAGE – KARANJ, TALUKA MANDAVI,
SURAT – 394 110

PAN : AALCR 5042 B

REG. NO. 127862
CIN NO. U24299GJ2021PTC127862



BY :-

P B VANKAWALA & CO.
CHARTERED ACCOUNTANTS

10/393, GANDHI CHOK,
PANI NI BHINT, OPP J K CHAMBERS,
BHAGATALAV,
SURAT – 395 003.



INDEPENDENT AUDITOR'S REPORT

To,
THE MEMBERS OF, RAYZON BIOCARE PRIVATE LIMITED,

Report on the Audit of Standalone Financial Statements

Opinion

We have audited the accompanying financial statements of "RAYZON BIOCARE PRIVATE LIMITED" ("the Company"), which comprise the standalone Balance Sheet as at March 31, 2024, and the standalone Statement of Profit and Loss for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information (hereinafter referred as "the standalone financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements read with the Notes Forming Part Of Accounts give the information required by the Companies Act, 2013, as amended ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2024 and its Loss for the year ended on that date.

Basis for Opinion

We conducted our audit of the Standalone Financial Statements in accordance with the Standards on Auditing (SAs), as specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Standalone Financial Statements" section of our report. We are independent of the Company in accordance with the "Code of Ethics" issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Standalone Financial Statements.





Information Other than the Standalone Financial Statements and Auditor's Report Thereon

The Company's management and Board of Directors is responsible for the other information. The other information comprises the information included in the Company's annual report, but does not include the Standalone Financial Statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone Financial Statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

Responsibility of Management's for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matter stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance of the Company in accordance with accounting principle generally accepted in India, including the Accounting Standards specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provision of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities; selection and application of appropriate accounting policies; making judgment and estimate that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial control that were operating effectively for ensuring the accuracy and completeness of accounting records, relevant to the preparation and presentation of the standalone financial statement that give a true and fare view and are free from material misstatement, whether due to fraud or error.





In preparing the Standalone Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibility for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management and the Board of Directors.





- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Standalone Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial Statements, including the disclosures, and whether the Standalone Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Standalone Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Standalone Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in

- planning the scope of our audit work and in evaluating the results of our work; and
- to evaluate the effect of any identified misstatements in the Standalone Financial Statement

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Standalone Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication





Report on Other Legal and Regulatory Requirements

1. The provisions of the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013 is not applicable to the Company since company is a **small company** as defined under section 2(85) of the companies Act, 2013.

As required under provisions of section 143(3) of the Act, we report that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;
- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as appears from our examination of such books;
- (c) The Balance Sheet and Statement of Profit and Loss dealt with by this Report are in agreement with the books of account;
- (d) In our opinion, the aforesaid financial statements comply with the accounting standards specified under section 133 of the Act, read with rules 7 of the Companies (Account) Rules, 2014.
- (e) On the basis of written representations received from the directors as on March 31, 2024, and taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2024, from being appointed as a director in terms of section 164(2) of the Act; and
- (f) Since the Company's turnover as per last audited Financial Statements is less than Rs.50 Crores and its borrowings from banks and financial institutions at any time during the year is less than Rs.25 Crores, the Company is exempted from getting an audit opinion with respect to the adequacy of the internal financial controls over financial reporting of the company and the operating effectiveness of such controls vide notification dated June 13, 2017;
- (g) The provisions of Section 197 read with Schedule V of the Act are not applicable to the Company for the period ended 31 March 2024 since the Company is not a public company as defined under section 2(71) of the Act. Accordingly, reporting under section 197(16) is not applicable





- (h) With respect to other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies(Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i) The Company does not have any pending litigations which would impact its financial position.
 - ii) The Company did not have any long term contracts including derivative contracts, as such the question of commenting on any material foreseeable losses thereon does not arise.
 - iii) There has not been an occasion in case of the Company during the year under report to transfer any sums to the Investor Education and Protection Fund. The question of delay in transferring such sums does not arise.
 - iv) (a) The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;
 - (b) The management has represented, that, to the best of its knowledge and belief, no funds have been received by the company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
 - (c) Based on such audit procedures that the auditor has considered reasonable and appropriate in the circumstances, nothing has come to their notice that has caused them to believe that the representations under sub-clause (i) and (ii) contain any material mis-statement.





- v) The Company has not declared any dividend during the year.
- vi) Based on our examination, which included test checks, the Company has used accounting software's for maintaining its books of account for the financial year ended March 31, 2024 which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of the audit trail feature being tampered with.

As proviso to rule 3(1) of the Companies (Accounts) Rules, 2024 is applicable from April 1, 2024, reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 on preservation of audit trail as per the statutory requirements for record retention is not applicable for the period ended as on 31st March, 2024.



PLACE : SURAT
DATE : SEPTEMBER 06, 2024

For, P B VANKAWALA & CO.
CHARTERED ACCOUNTANTS
ICAI Firm Reg. No. 0132418W

(Signature)
(CA PRASHANT PRAKASH VANKAWALA)
PARTNER

MEMBERSHIP NO: 140231
UDIN : 24140231BKEAPV4087
10/393, GANDHI CHOWK, PANI NI BHINT,
BHAGATALAV, SURAT - 395 003

RAYZON BIO CARE PRIVATE LIMITED

CIN : U24299GJ2021PTC127862

BALANCE SHEET AS AT 31st MARCH, 2024

(All amounts are ₹. in Lacs)

	Note No.	AS AT 31.03.2024	AS AT 31.03.2023
I. EQUITY AND LIABILITIES			
(1) SHARE HOLDERS' FUND			
(a) Share Capital	1	2.00	2.00
(b) Reserve & Surplus	2	(15.56)	(13.55)
		(13.56)	(11.55)
(2) NON - CURRENT LIABILITIES			
(a) Long Term Borrowings	3	69.50	69.00
		69.50	69.00
(3) CURRENT LIABILITIES			
(a) Trade Payables	4	2.47	3.20
(b) Other Current Liabilities		-	-
(c) Short - Term Provisions		-	-
		2.47	3.20
TOTAL		58.41	60.65
II. ASSETS			
NON - CURRENT ASSETS			
(1) FIXED ASSETS			
(a) Tangible Assets	5	0.07	0.20
(b) Non - Current Investments		-	-
(c) Deffered Tax Assets	6	0.01	0.00
(d) Long Term Loans and Advances	7	3.28	3.07
		3.37	3.26
(2) CURRENT ASSETS			
(a) Inventories	8	42.39	44.38
(b) Trade Receivables	9	0.83	0.82
(c) Other Current Assets	10	10.26	10.52
(d) Cash and Cash Equivalents	11	1.56	1.66
		55.04	57.39
TOTAL		58.41	60.65

As per report of our even date attached
For, P B VANKAWALA & CO.
CHARTERED ACCOUNTANTS.
ICAI FIRM REG. NO 0132418W

(CA. PRASHANT PRAKASH VANKAWALA)
PARTNER
MEMBERSHIP NO : 140231
SURAT : 06 SEPTEMBER, 2024
UDIN : 24140231BKEAPV4087



For and on behalf of the Board
RAYZON BIO CARE PRIVATE LIMITED

(Signature)

DIRECTOR
(GAURAV DHIRUBHAI NAKARANI)
(DIN NO: 08767649)

(Signature)
DIRECTOR
(DARSHIL BHARATBHAI GONDALIYA)
(DIN NO: 08767866)

RAYZON BIOCARE PRIVATE LIMITED

CIN : U24299GJ2021PTC127862

PROFIT & LOSS ACCOUNT FOR THE YEAR ENDED 31st MARCH, 2024

(All amounts are ₹. in Lacs)


	Note No.	For The Year Ended 31.03.2024	For The Year Ended 31.03.2023
I. Revenue From Operations	12	2.29	5.40
II. Other Income	13	0.22	0.04
III. TOTAL REVENUE (I + II)		2.51	5.43
IV EXPENSES			
(a) Purchase of Stock In Trade	14	-	48.38
(b) Changes in Inventories of Traded goods	15	1.99	(44.38)
(c) Employee Benefits Expenses	16	0.66	0.25
(d) Finance Costs	17	0.00	0.00
(e) Depreciation and Amortization Expenses	18	0.12	0.05
(f) Other Expenses	19	1.76	14.69
TOTAL EXPENSES		4.54	18.98
V. PROFIT FOR THE YEAR BEFORE TAX ADJUSTMENTS AND TAXES (III - IV)		(2.02)	(13.55)
VI. PROFIT BEFORE TAXES		(2.02)	(13.55)
VII. TAX EXPENSES	20		
(a) Current Tax		-	-
(b) Deffered Tax		(0.01)	(0.00)
		(0.01)	(0.00)
VIII. PROFIT AFTER TAXATION (VI - VII)		(2.01)	(13.55)
IX. EARNING PER SHARE (In ₹)		(10.07)	(67.73)

As per report of our even date attached

For, P B VANKAWALA & CO.

CHARTERED ACCOUNTANTS.

ICAI FIRM REG. NO 0132418W


(CA. PRASHANT PRAKASH VANKAWALA)
PARTNER


MEMBERSHIP NO : 140231

SURAT : 06 SEPTEMBER, 2024


UDIN : 24140231BKEAPV4087



For and on behalf of the Board
RAYZON BIOCARE PRIVATE LIMITED



DIRECTOR
(GAURAV DHIRUBHAI NAKARANI)
(DIN NO: 08767649)


DIRECTOR
(DARSHIL BHARATBHAI GONDALIYA)
(DIN NO: 08767866)

RAYZON BIO CARE PRIVATE LIMITED

NOTES FORMING PART OF THE BALANCE SHEET AS AT 31st MARCH, 2024

(All amounts are ₹. in Lacs)

NOTE 1 : SHARE CAPITAL

PARTICULARS		AS AT 31.03.2024	AS AT 31.03.2023
Authorised 1,00,000 Equity Shares of ₹ 10/- Each		10.00	10.00
Issued, Subscribed, Paidup 20,000 Equity Shares of ₹ 10/- Each		2.00	2.00

NOTE 1.1 : DETAILS OF SHARES HELD BY EACH SHARE HOLDERS MORE THAN 5% OF SHARES

NAME OF THE SHARE HOLDER	% of Holding	AS AT 31.03.2024 No of Shares Held	AS AT 31.03.2023 No of Shares Held
1. Chirag Devchandbhai Nakarani	30.00%	6,000	6,000
2. Hardik Ashokbhai Korhiya	30.00%	6,000	6,000
3. Gaurav Dhirubhai Nakarani	12.50%	2,500	2,500
4. Darshil Bharatbhai Nakarani	12.50%	2,500	2,500
5. Sanketkumar Bharatbhai Gondaliya	15.00%	3,000	3,000

NOTE 1.2 : SHARE HOLDING OF PROMOTERS

Shares held by promoters as at 31 March, 2024

NAME OF THE SHARE HOLDER	% of Holding	AS AT 31.03.2024 No of Shares Held	% Change During The Year
1. Chirag Devchandbhai Nakarani	30.00%	6,000	-
2. Hardik Ashokbhai Korhiya	30.00%	6,000	-
3. Gaurav Dhirubhai Nakarani	12.50%	2,500	-
4. Darshil Bharatbhai Nakarani	12.50%	2,500	-
5. Sanketkumar Bharatbhai Gondaliya	15.00%	3,000	-

Shares held by promoters as at 31 March, 2023

NAME OF THE SHARE HOLDER	% of Holding	AS AT 31.03.2023 No of Shares Held	% Change During The Year
1. Chirag Devchandbhai Nakarani	30.00%	6,000	-20.00%
2. Hardik Ashokbhai Korhiya	30.00%	6,000	-20.00%
3. Gaurav Dhirubhai Nakarani	12.50%	2,500	12.50%
4. Darshil Bharatbhai Nakarani	12.50%	2,500	12.50%
5. Sanketkumar Bharatbhai Gondaliya	15.00%	3,000	15.00%

Breakup of Equity Capital

NAME OF THE SHARE HOLDER	% of Holding	AS AT 31.03.2024 No of Shares Held	AS AT 31.03.2023 No of Shares Held
1. Director and Related Parties	100.00%	20,000	20,000



RAYZON BIOCARE PRIVATE LIMITED

NOTES FORMING PART OF THE BALANCE SHEET AS AT 31st MARCH, 2024

(All amounts are ₹. in Lacs)

PARTICULARS	AS AT 31.03.2024	AS AT 31.03.2023
NOTE 2 : RESERVE AND SURPLUS		
2.1 PROFIT AND LOSS ACCOUNT		
Balance as Per Last Balance Sheet	(13.55)	-
Add : Profit/ (Loss) for the Year	(2.01)	(13.55)
Closing Balance	(15.56)	(13.55)
NOTE 3 : LONG TERM BORROWINGS		
Loan & Advances from Related parties	69.50	69.00
	69.50	69.00
NOTE 4 : TRADE PAYABLES		
4.1 SUNDRY CREDITORS :		
For Material Purchase	0.26	0.26
For Expenses	0.38	1.15
For Liabilities	-	-
For Advance Received From Customer	1.83	1.78
	2.47	3.20
NOTE 6 : DEFERRED TAXES		
6.1 DEFERRED TAX ASSETS :		
Timing Difference on account of Depreciation	0.01	0.00
	0.01	0.00
NOTE 7 : LONG TERM LOANS, ADVANCES AND DEPOSITS		
7.1 SECURITY DEPOSITS-UNSECURED CONSIDERED GOODS		
Fixed Deposit With Bank (Including Accrued Interest)	3.25	3.04
Deposit With Others	0.03	0.03
	3.28	3.07
NOTE 8 : INVENTORIES		
(At Cost or Market Value whichever is Lower as certified by Directors)		
Material	42.39	44.38
	42.39	44.38
NOTE 9 : TRADE RECEIVABLES		
SUNDRY DEBTORS UNSECURED CONSIDERED GOODS		
Due for a Period Less than Six Months	0.34	0.82
Due for a Period Exceeding Six Months	0.50	-
	0.83	0.82
NOTE 10 : OTHER CURRENT ASSETS		
10.1 UNSECURED, CONSIDERED GOODS UNLESS OTHERWISE STATED		
Advance Paid to Suppliers	-	0.11
GST Credit Balance	10.09	10.24
GST Cash Balance	0.03	0.01
TDS & TCS	0.02	0.01
Preliminary Expense	0.12	0.16
	10.26	10.52
NOTE 11 : CASH AND CASH EQUIVALENTS		
BALANCE WITH BANKS		
With Schedule Bank		
HDFC Bank	0.20	0.20
ICICI Bank	1.27	1.29
Cash on Hand	0.09	0.16
	1.56	1.66



RAYZON BIOCARE PRIVATE LIMITED

SCHEDULE FORMING PART OF THE BALANCE SHEET AS AT 31st MARCH, 2024

NOTE - 5

(All amounts are ₹. in Lacs)

Particular	Rate (WDV)	Gross Block				Depreciation			Net	
		Total As on 01.04.2023	Addition	Deduction	Total As on 31.03.2024	As on 01.04.2023	For The Year	Deduction	Total As on 31.03.2024	Total As on 31.03.2023
Computer	63.16%	0.15	-		0.15	0.03	0.08		0.11	0.13
Printer	63.16%	0.10			0.10	0.03	0.05		0.07	0.07
Grand Total		0.25	-	-	0.25	0.05	0.12	-	0.18	0.20
Previous		-	0.25	-	0.25	-	0.05	-	0.05	0.20
										-

Notes :

01. Pursuant to enactment of Companies Act 2013, Effective from April 1, 2015 the company has charged depreciation based upon the useful life of fixed assets as per requirement of Schedule II of the Companies Act 2013. Depreciation is provided on Written Down Value (WDV) method over the estimated useful life of the asset estimated by the management which is equal to the useful life prescribed under schedule II to the Companies Act, 2013.



RAYZON BIOCARE PRIVATE LIMITED

NOTES FORMING PART OF THE STATEMENT OF PROFIT & LOSS A/C AS AT 31st MARCH, 2024

(All amounts are ₹. in Lacs)

PARTICULARS	AS AT 31.03.2024	AS AT 31.03.2023
NOTE 12 : REVENUE FROM OPERATIONS		
12.1 Sale of Products	2.29	5.40
	2.29	5.40
NOTE 13 : OTHER INCOME		
13.1 INTEREST INCOME		
FD Interest Income (Accrued)	0.22	0.04
Interest on Income Tax Refund	0.00	-
	0.22	0.04
NOTE 14 : PURCHASE OF STOCK IN TRADE		
14.1 PURCHASE (TRADED GOODS)		
Purchase During the Year	-	48.38
	-	48.38
NOTE 15 : CHANGES IN INVENTORIES OF TRADED GOODS		
15.1 CLOSING STOCK OF TRADED GOODS		
Traded Goods	42.39	44.38
TOTAL CLOSING STOCK	42.39	44.38
15.2 OPENING STOCK OF TRADED GOODS		
Traded Goods	44.38	-
TOTAL OPENING STOCK	44.38	-
INCREASE(-) / DECREASE IN STOCK	1.99	(44.38)
NOTE 16 : EMPLOYEE BENEFIT EXPENSES		
Salary & Bonus	0.66	0.25
	0.66	0.25
NOTE 17 : FINANCE COST		
17.1 OTHER EXPENSES		
Bank Charges	0.00	0.00
	0.00	0.00
NOTE 18 : DEPRECIATION AND AMORTISATION EXPENSES		
Depreciation on Tangible Assets	0.12	0.05
	0.12	0.05



RAYZON BIO CARE PRIVATE LIMITED

NOTES FORMING PART OF THE STATEMENT OF PROFIT & LOSS A/C AS AT 31st MARCH, 2024

(All amounts are ₹. in Lacs)

PARTICULARS	AS AT 31.03.2024	AS AT 31.03.2023
NOTE 19 : OTHER EXPENSES		
19.1 DIRECT EXPENSE		
Frieght Charges	0.06	1.16
19.2 ADMINISTRATIVE AND GENERAL EXPENSES		
Printing & Stationery Expense	-	0.25
Information Technology Expense	-	0.15
Office Expense	0.13	0.11
Die & Mould Expense	-	1.77
Travelling & Conveyance Expense	-	0.03
Legal Professional Charges	0.14	1.06
Interest on Late Payment of TDS	-	0.02
Round Off	(0.00)	0.00
Prilimentary Expense Written Off	0.04	0.04
19.3 AUDITORS REMUNERATION		
Audit Fees	0.08	0.13
19.4 SELLING AND DISTRIBUTION EXPENSE		
Commission & Advertising Promotional Expenses	1.31	9.97
	1.76	14.69
NOTE 20 : TAX EXPENSES		
Current Tax Provision	-	-
Deferred tax	(0.01)	(0.00)
	(0.01)	(0.00)

As per report of our even date attached
For, P B VANKAWALA & CO.
CHARTERED ACCOUNTANTS.
ICAI FIRM REG. NO 0132418W

(CA. PRASHANT PRAKASH VANKAWALA)
PARTNER
MEMBERSHIP NO : 140231
SURAT : 06 SEPTEMBER, 2024
UDIN : 24140231BKEAPV4087



For and on behalf of the Board
RAYZON BIO CARE PRIVATE LIMITED


DIRECTOR
(GAURAV DHIRUBHAI NAKARANI)
(DIN NO: 08767649)


DIRECTOR
(DARSHIL BHARATBHAI GONDALIYA)
(DIN NO: 08767866)

RAYZON BIOCARE PRIVATE LIMITED

CIN : U24299GJ2021PTC127862

NOTES ON ACCOUNTS FOR THE YEAR ENDED MARCH 31, 2024

(All amounts are ₹. in Lacs)

Annexure : A : Trade Payables Ageing Schedule

as at 31/03/2024

Particulars	Total			
	Less than 1 year	1-2 years	2-3 years	More than 3 years
(i) MSME				
Trade Payable				
(ii) Others				-
Trade Payable & Expense Payable	0.08	0.56		0.64
(iii) Disputed dues - MSME				-
(iv) Disputed dues - Others				
Total	0.08	0.56		0.64



RAYZON BIOCARE PRIVATE LIMITED

CIN : U24299GJ2021PTC127862

NOTES ON ACCOUNTS FOR THE YEAR ENDED MARCH 31, 2024

(All amounts are ₹. in Lacs)

Annexure : B ; Trade Receivable Ageing Schedule

as at 31/03/2024

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables - considered good	0.34	0.50				0.83
(ii) Undisputed Trade Receivables - considered doubtful						
(iii) Disputed Trade Receivables considered good						
(iv) Disputed Trade Receivables considered doubtful						
Total	0.34	0.50	-	-	-	0.83



RAYZON BIO CARE PRIVATE LIMITED.

NOTES FORMING PART OF THE ACCOUNTS FOR THE YEAR ENDED MARCH 31, 2024.

(All amounts are in Lacs of Indian Rupees (₹), unless otherwise stated)

1. CORPORATE INFORMATION:

Rayzon Biocare Private Limited (hereinafter referred as "the Company") is a private limited company incorporated on December 09, 2021 domiciled in India. The registered office is located at Block No. 105, Near Hariya Talav, B/h Aron Pipes, Village - Karanj, Taluka Mandvi, Surat - 394 110. Identification No: U242996J2021PTC127862 issued by Registrar of Company Ahmedabad, Gujarat. The Company is primarily engaged in the business of Trading of Cosmetic Item.

2. SIGNIFICANT ACCOUNTING POLICIES:

i) Basis of Accounting:

Financial Statements are prepared under historical cost convention on accrual basis in accordance with the requirement of the Companies Act 2013. The accounting policies consistently applied by the company. The company functional and presentation currency is Indian ₹ (INR) and all values are rounded to the nearest million except when otherwise indicated.

ii) Classification of Assets and Liabilities into Current/Non-Current

The Company presents assets and liabilities in the balance sheet based on current/non-current classification

Current Assets:

An asset is classified as current when it is expected to be realized, or intended to be sold or consumed in the normal operating cycle, or within 12 months after the reporting period, or it is cash or a cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period

Non-Current Assets:

All assets other than Current Assets are classified as non-current.


Current Liabilities:

A liability is classified as current when it is expected to be settled in the normal operating cycle, or it is due to be settled within 12 months after the reporting period, or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period.

Non-Current Liabilities:

All liabilities other than Current Liabilities are classified as non-current.

The Company's operating cycle is the time between the acquisition of assets for processing and their realization in cash or cash equivalents. The Company has identified less than 12 months as its operating cycle.



ii) **Fixed Assets & Depreciation:**

- A. Fixed Assets are stated at cost of acquisition, net of accumulated depreciation and accumulated impairment losses, if any. The Cost comprises purchase price, borrowing costs if capitalization criteria are met and directly attributable cost of bringing the assets to its working condition for the intended use. Any trade discount and rebates are deducted in arriving at the purchase price.
- B. Depreciation is provided using Written Down Value (WDV) method over the estimated useful lives of the assets as prescribed under Schedule II to the Companies Act, 2013. The residual values, useful lives, and methods of depreciation are reviewed at each financial year-end and adjusted prospectively if necessary.
- C. Depreciation on addition/deletion during the year is provided on prorata basis.
- D. No Assets have been revalued during the year.

iii) **Retirement Benefits :**

Gratuity liability is not provided and will be accounted as and when paid. The company has continued with the Government P.F. system wherein family pension plan also included therein.

iv) **Inventory :**

- A. Inventory are stated at cost or net realizable value whichever is lower excluding of taxes.
- B. Cost of Inventories comprises all cost of purchase and other cost incurred in bringing inventories to their present location and condition. Cost in case of work in progress is determined based on the actual expenditure attributable to the said work till the end of the reporting period.

v) **Provision for Taxation:**

Provision for taxation is calculated as per "Total Income" returnable under Income Tax Act, 1961.

vi) **Other Accounting Policies :**

- A. These are consistent with the generally accepted accounting practices.
 - B. Revenue is recognized and expenditure is accounted for on their accrual.
- vii) In the opinion of the board, the Current Assets, Loans & Advances are approximately of the value stated if realized in the ordinary course of business. The Provision for all known liabilities is adequate and not in excess of the amount reasonably necessary.
- viii) Debit and credit balances and deposits are subject to confirmation and reconciliation if any.
- ix) In accordance with accounting standard 22 "Accounting for Taxes on Income" 0.01 is provided as deferred tax assets for the year ended 31st March, 2024 in respect of Depreciation on fixed assets.



	Particular	Amount
(i)	Deferred Tax Assets as on 01-04-2023	0.00
(ii)	Deferred Tax Assets on account of timing difference in depreciation	0.01
	Deferred Tax Assets as on 31-03-2024	0.01

x) Managerial remuneration to Directors

	Current Year	Previous Year
Director Remuneration	NIL	NIL
Director Sitting Fees	NIL	NIL

xi) Information pursuant to the provisions of paragraphs 3, 4C, & 4D of Part

Expenditure in respect of employees:

In terms of the provision of Section 217 (2A) of the Companies Act, 1956, read with the Companies (Particulars of Employees) Rules, 1975, as amended, the information be treated as mention below.

None of the stated employee / director drawing salary equals to or above the limits mentioned in the said Section and Rules.

3. CONTINGENT LIABILITY & COMMENTS:-

(i) Contingent Liability - NIL

(ii) Commitments :-

(a) Estimated amount of contracts remaining to be executed on capital account and not provided for Rs. NIL (P.Y. Rs. NIL)

(b) Uncalled Liability on shares and other investment partly paid Rs. NIL (P.Y. Rs. NIL)

(c) Other commitments Rs. NIL (P.Y. Rs. NIL)

4. Expenditure in Foreign Currency:- NIL

5. Earning In Foreign Currency:- NIL

6. Auditors Remuneration:-


Sr. No.	Particulars	F.Y. 23-24	F.Y. 22-23
(a)	Audit Fees	0.075	0.075

7. Earnings Per Share:-

(Amount In ₹)

Sr. No.	Particulars	F.Y. 23-24	F.Y. 22-23
(a)	Net Profit After Tax	(2,01,318)	(13,54,612)
(b)	Number of Equity Shares	20,000	20,000
(c)	Earnings Per Share	(10.07)	(67.73)

(a) Earnings per share has been computed by dividing the profit for the year by the Number of Equity Shares.



8. Disclosures as required under the Micro, Small and Medium Enterprises Development Act, 2006 (MSMED ACT):-

Sr. No.	PARTICULARS	As At March 31, 2024	As At March 31, 2023
A.	Principal amount due to suppliers register under the MSMED Act and remaining unpaid as at year end.	-	-
B.	Interest due to suppliers register under the MSMED Act and remaining unpaid as at year end.	-	-
C.	Principal amounts paid to suppliers register under the MSMED Act, beyond the appointed day during the year	-	-
D.	Interest Paid, other than Under Section 16 of MSMED Act, to suppliers register under the MSMED Act, beyond the appointed day during year	-	-
E.	Interest paid, Under Section 16 of MSMED Act, to suppliers registered under the MSMED Act, beyond the appointed day during year	-	-
F.	Interest due and payable towards suppliers registered under the MSMED Act, for payments already made	-	-

The above information disclosure regarding Trade Payable of Micro, Small and Medium Enterprises is made by Management as per information from suppliers' regarding their status under the Micro, Small and Medium Enterprises Development Act, 2006 and relied upon by Auditors.

Further, as per the representation given by the management that the payment terms as agreed with the vendors takes care of the same in the rates and hence have not received any claims for interest from any supplier as at balance sheet date.

9. Disclosure Pursuant to Indian Accounting Standard 19 'Employee Benefits':-

The Company has recognized the following amounts towards defined contribution plans as an expenses and included in the Statement of Profit and Loss.

Sr. No.	Particulars	F.Y. 23-24	F.Y. 22-23
(a)	Provident Fund	-	-

The Company has not provided for Post-Employment Benefits and other long term employee benefits under defined benefit plans on accrual basis but provides the same as and when they become due for payment.



10. Cash flows statement

Statement of cash flows is prepared segregating the cash flows into operating, investing and financing activities. Cash flows are reported using the indirect method, whereby net profit for the period is adjusted for the effects of transactions of non-cash nature, working capital changes, any deferrals or accruals of past or future operating cash receipts or payments and items of income or expenses associated with investing or financing cash flows. For presentation in the statement of cash flows, cash and cash equivalents include cash on hand, cash at banks, other short-term deposits and highly liquid investments with original maturity of three months or less that are readily convertible into cash.

11. Segment Reporting:-

In line with Ind AS - 108 on 'Operating Segments', taking into account the organizational structure, product type as well as the differing risks and returns criterion, The Company is engaged in only one reportable segment.

12. Income Tax

(a) Income Tax Expense in the statement of profit and loss consists of:

Sr. No.	Particulars	F.Y. 23-24	F.Y. 22-23
(a)	Current Tax :		
	(a) In respect of the current period	-	-
	(b) In respect of the prior period	-	-
(b)	Deferred Tax :		
	(a) In respect of the current period	(0.011)	(0.001)
(c)	Income Tax Expense recognized in the statement of Profit or Loss	-	-

(b) The reconciliation between the provision of income tax of the Company and amounts computed by applying the Indian statutory income tax rate to profit before taxes is as follows:

Particulars	F.Y. 23-24	F.Y. 22-23
Profit / (Loss) Before Tax	(2.02)	(13.55)
Enacted Income Tax Rate in India	25.17 %	-
Computed Expected Tax Expenses	-	-
Effect of		
(a) Deferred Tax	(0.011)	(0.001)
(b) Adjustment of Current Tax for Prior Periods	-	-
(c) Impact of Changes on account of Computation	-	-
Income Tax expense recognized in the statement of profit or loss	-	-



13. Previous year figures have been regrouped/rearranged wherever necessary.

14. Additional Regulatory Information:

- (i) The Company does not have any benami property held in its name. No proceedings have been initiated on or are pending against the Company for holding benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and Rules made thereunder.
- (ii) The Company has not been declared willful defaulter by any bank or financial institution or other lender or government or any government authority.
- (iii) The Company has complied with the requirement with respect to number of layers as prescribed under section 2(87) of the Companies Act, 2013 read with the Companies (Restriction on number of layers) Rules, 2017.
- (iv) **Utilisation of borrowed funds and share premium**
 - I) The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (intermediaries) with the understanding that the intermediary shall:
 - (a) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or
 - (b) Provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries
 - II) The Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether record in writing or otherwise) that the company shall:
 - (a) Directly or Indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the funding party (Ultimate beneficiaries) or
 - (b) Provide any guarantee, security or the like on behalf of the ultimate beneficiaries
- (v) There is no income surrendered or disclosed as income during the year in tax assessments under the Income Tax Act, 1961 (such as search or survey), that has not been recorded in the books of account.
- (vi) The Company has not traded or invested in crypto currency or virtual currency during the year.
- (vii) The Company does not have any charges or satisfaction of charges which is yet to be registered with Registrar of Companies beyond the statutory period in respect of loans taken/repaid during the year.
- (viii) No Borrowings from banks or financial institutions on the basis of security of current assets.
- (ix) Loans give to related parties:-

The Company does not give any loan to related parties.
- (x) Transactions with Companies Struck off under the Company Laws:- NIL



15. Related Party Relationship and Transaction

(a) Key Management Personnel:

- Chirag Devchandbhai Nakarani
- Hardik Ashokbhai Kothiya
- Gaurav Dhirubhai Nakarani
- Darshil Bharatbhai Gondaliya
- Sanketkumar Bharatbhai Kothiya

(b) Enterprises Controlled by Key Managerial Personnel & their relatives

- Rayzon Solar Private Limited
- Rayzon Green Private Limited (Formally Known as Better Energies Private Limited)

Transactions with Related Parties

Particulars	Key Management Personnel & relatives of Key Management Personnel		Enterprises Controlled by Key Management Personnel	
	F.Y. 23-24	F.Y. 22-23	F.Y. 23-24	F.Y. 22-23
(a) Loans Taken				
Chirag D Nakarani	0.50	34.50		
Darshil B Gondaliya	-	34.50		
(b) Advance Received				
Rayzon Green Private Limited (Formally Known as Better Energies Private Limited)	0.05	-		
(c) Purchase of Goods				
Rayzon Solar Private Limited	-	-	-	2.64



16. Key Financial Ratios:-

(a) Current Ratio

Particulars	As at March 31, 2024	As at March 31, 2023
Current Assets	55.04	57.39
Current Liabilities	2.47	3.20
Current Ratios (In Times)	22.47	17.96

(b) Debt Equity Ratio

Particulars	As at March 31, 2024	As at March 31, 2023
Total Borrowings	69.50	69.00
Total Equity	(13.56)	(11.55)
Debt to Equity Ratio (In Times)	(5.13)	(5.98)

(c) Debt Service Coverage Ratio

Particulars	As at March 31, 2024	As at March 31, 2023
Earning for Debt Service	(1.89)	(13.49)
Debt Services	-	-
Debt Service Coverage Ratio (In Times)	NA	NA

Explanation: Total Borrowing are from Director and Long Term.

(d) Return of Equity Ratio

Particulars	As at March 31, 2024	As at March 31, 2023
Profit After Tax	(2.01)	(13.55)
Average Share Holder's Fund	(12.55)	(4.78)
Return on Equity Ratio (In %)	(16.04)	(283.69)

Explanation: Due to Low revenue from operation during the year.

(e) Inventory Turnover Ratio

Particulars	As at March 31, 2024	As at March 31, 2023
Cost of Goods Sold	1.99	3.99
Opening Inventories	44.38	-
Closing Inventories	42.39	44.38
Average Inventories	43.39	22.19
Inventory Turnover Ratio (In Times)	0.05	0.18

Explanation: Due to Low revenue from operation during the year.



(f) Trade Receivable Turnover Ratio

Particulars	As at March 31, 2024	As at March 31, 2023
Revenue From Operations	2.51	5.43
Opening Trade Receivable	0.82	-
Closing Trade Receivable	0.83	0.82
Average Trade Receivable	0.82	0.41
Trade Receivable Turnover Ratio (In Days)	120	27

Explanation: Due to Low revenue from operation during the year.

(g) Trade Payable Turnover Ratio

Particulars	As at March 31, 2024	As at March 31, 2023
Purchase of Goods	-	48.38
Opening Trade Payable	3.20	-
Closing Trade Payable	2.47	3.20
Average Trade Payable	2.83	1.60
Trade Payable Turnover Ratio (In Days)	NA	12.06

(h) Net Working Capital Turnover Ratio

Particulars	As at March 31, 2024	As at March 31, 2023
Revenue from Operations	2.51	5.43
Closing Working Capital	52.57	54.19
Net Working Capital Turnover Ratio (In Times)	0.05	0.10

Explanation: Due to Low revenue from operation during the year.

(i) Net Profit Ratio

Particulars	As at March 31, 2024	As at March 31, 2023
Profit After Tax	(2.01)	(13.55)
Revenue from Operations	2.51	5.43
Net Profit Ratio (In %)	(80.08)	(249.54)

Explanation: Due to Low revenue from operation during the year.

(j) Return on Capital Employed

Particulars	As at March 31, 2024	As at March 31, 2023
Profit Before Tax & Finance Cost	(2.02)	(13.55)
Capital Employed	(13.56)	(11.55)
Return on Capital Employed (In %)	(14.92)	(117.33)

Explanation: Due to Low revenue from operation during the year.

RAYZON BIOCARE PRIVATE LIMITED

CIN : U24299GJ2021PTC127862

BALANCE SHEET AS AT 31st MARCH, 2024

(All amounts are in Indian ₹)

	Note No.	AS AT 31.03.2024	AS AT 31.03.2023
I. EQUITY AND LIABILITIES			
(1) SHARE HOLDERS' FUND			
(a) Share Capital	1	2,00,000.00	2,00,000.00
(b) Reserve & Surplus	2	(15,55,930.00)	(13,54,612.00)
		(13,55,930.00)	(11,54,612.00)
(2) NON - CURRENT LIABILITIES			
(a) Long Term Borrowings	3	69,50,000.00	69,00,000.00
		69,50,000.00	69,00,000.00
(3) CURRENT LIABILITIES			
(a) Trade Payables	4	2,47,193.00	3,19,558.00
(b) Other Current Liabilities		-	-
(c) Short - Term Provisions		-	-
		2,47,193.00	3,19,558.00
TOTAL		58,41,263.00	60,64,946.00
II. ASSETS			
NON - CURRENT ASSETS			
(1) FIXED ASSETS			
(a) Tangible Assets	5	7,257.00	19,699.00
(b) Non - Current Investments		-	-
(c) Deffered Tax Assets	6	1,214.00	114.00
(d) Long Term Loans and Advances	7	3,28,365.00	3,06,510.00
		3,36,836.00	3,26,323.00
(2) CURRENT ASSETS			
(a) Inventories	8	42,39,276.00	44,38,402.00
(b) Trade Receivables	9	83,108.00	81,661.00
(c) Other Current Assets	10	10,26,361.00	10,52,445.00
(d) Cash and Cash Equivalents	11	1,55,682.00	1,66,115.00
		55,04,427.00	57,38,623.00
TOTAL		58,41,263.00	60,64,946.00

As per report of our even date attached
For, P B VANKAWALA & CO.
CHARTERED ACCOUNTANTS.
ICAI FIRM REG. NO 0132418W

(CA. PRASHANT PRAKASH VANKAWALA)
PARTNER
MEMBERSHIP NO : 140231
SURAT : 06 SEPTEMBER, 2024
UDIN : 24140231BKEAPV4087



For and on behalf of the Board
RAYZON BIOCARE PRIVATE LIMITED

(Signature)

DIRECTOR
(GAURAV DHIRUBHAI NAKARANI)
(DIN NO: 08767649)

(Signature)
DIRECTOR
(DARSHIL BHARATBHAI GONDALIYA)
(DIN NO: 08767866)

RAYZON BIOCARE PRIVATE LIMITED

CIN : U24299GJ2021PTC127862

PROFIT & LOSS ACCOUNT FOR THE YEAR ENDED 31st MARCH, 2024

(All amounts are in Indian ₹)


	Note No.	For The Year Ended 31.03.2024	For The Year Ended 31.03.2023
I. Revenue From Operations	12	2,29,311.00	5,39,950.00
II. Other Income	13	21,879.00	3,510.00
III. TOTAL REVENUE (I + II)		2,51,190.00	5,43,460.00
IV EXPENSES			
(a) Purchase of Stock In Trade	14	-	48,37,672.00
(b) Changes in Inventories of Traded goods	15	1,99,126.00	(44,38,402.00)
(c) Employee Benefits Expenses	16	66,300.00	24,600.00
(d) Finance Costs	17	136.00	26.00
(e) Depreciation and Amortization Expenses	18	12,442.00	5,471.00
(f) Other Expenses	19	1,75,604.00	14,68,819.00
TOTAL EXPENSES		4,53,608.00	18,98,186.00
V. PROFIT FOR THE YEAR BEFORE TAX ADJUSTMENTS AND TAXES (III - IV)		(2,02,418.00)	(13,54,726.00)
VI. PROFIT BEFORE TAXES		(2,02,418.00)	(13,54,726.00)
VII. TAX EXPENSES	20		
(a) Current Tax		-	-
(b) Defferred Tax		(1,100.00)	(114.00)
		(1,100.00)	(114.00)
VIII. PROFIT AFTER TAXATION (VI - VII)		(2,01,318.00)	(13,54,612.00)
IX. EARNING PER SHARE		(10.07)	(67.73)

As per report of our even date attached
For, P B VANKAWALA & CO.
CHARTERED ACCOUNTANTS.
ICAI FIRM REG. NO 0132418W

(CA. PRASHANT PRAKASH VANKAWALA)
PARTNER
MEMBERSHIP NO : 140231
SURAT : 06 SEPTEMBER, 2024
UDIN : 24140231BKEAPV4087



For and on behalf of the Board
RAYZON BIOCARE PRIVATE LIMITED


DIRECTOR
(GAURAV DHIRUBHAI NAKARANI)
(DIN NO: 08767649)


DIRECTOR
(DARSHIL BHARATBHAI GONDALIYA)
(DIN NO: 08767866)

RAYZON BIOCARE PRIVATE LIMITED

NOTES FORMING PART OF THE BALANCE SHEET AS AT 31st MARCH, 2024

(All amounts are in Indian ₹)

NOTE 1 : SHARE CAPITAL

PARTICULARS		AS AT 31.03.2024	AS AT 31.03.2023
Authorised 1,00,000 Equity Shares of ₹ 10/- Each		10,00,000.00	10,00,000.00
Issued, Subscribed, Paidup 20,000 Equity Shares of ₹ 10/- Each		2,00,000.00	2,00,000.00

NOTE 1.1 : DETAILS OF SHARES HELD BY EACH SHARE HOLDERS MORE THAN 5% OF SHARES

NAME OF THE SHARE HOLDER	% of Holding	AS AT 31.03.2024 No of Shares Held	AS AT 31.03.2023 No of Shares Held
1. Chirag Devchandbhai Nekarani	30.00%	6,000	6,000
2. Hardik Ashokbhai Korhiya	30.00%	6,000	6,000
3. Gaurav Dhirubhai Nekarani	12.50%	2,500	2,500
4. Darshil Bharatbhai Nekarani	12.50%	2,500	2,500
5. Sanketkumar Bharatbhai Gondaliya	15.00%	3,000	3,000

NOTE 1.2 : SHARE HOLDING OF PROMOTERS

Shares held by promoters as at 31 March, 2024

NAME OF THE SHARE HOLDER	% of Holding	AS AT 31.03.2024 No of Shares Held	% Change During The Year
1. Chirag Devchandbhai Nekarani	30.00%	6,000	-
2. Hardik Ashokbhai Korhiya	30.00%	6,000	-
3. Gaurav Dhirubhai Nekarani	12.50%	2,500	-
4. Darshil Bharatbhai Nekarani	12.50%	2,500	-
5. Sanketkumar Bharatbhai Gondaliya	15.00%	3,000	-

Shares held by promoters as at 31 March, 2023

NAME OF THE SHARE HOLDER	% of Holding	AS AT 31.03.2023 No of Shares Held	% Change During The Year
1. Chirag Devchandbhai Nekarani	30.00%	6,000	-20.00%
2. Hardik Ashokbhai Korhiya	30.00%	6,000	-20.00%
3. Gaurav Dhirubhai Nekarani	12.50%	2,500	12.50%
4. Darshil Bharatbhai Nekarani	12.50%	2,500	12.50%
5. Sanketkumar Bharatbhai Gondaliya	15.00%	3,000	15.00%

Breakup of Equity Capital

NAME OF THE SHARE HOLDER	% of Holding	AS AT 31.03.2024 No of Shares Held	AS AT 31.03.2023 No of Shares Held
1. Director and Related Parties	100.00%	20,000	20,000



RAYZON BIOCARE PRIVATE LIMITED

NOTES FORMING PART OF THE BALANCE SHEET AS AT 31st MARCH, 2024

(All amounts are in Indian ₹)

PARTICULARS	AS AT 31.03.2024	AS AT 31.03.2023
NOTE 2 : RESERVE AND SURPLUS		
2.1 PROFIT AND LOSS ACCOUNT		
Balance as Per Last Balance Sheet	(13,54,612.00)	-
Add : Profit/ (Loss) for the Year	(2,01,318.00)	(13,54,612.00)
Closing Balance	(15,55,930.00)	(13,54,612.00)
NOTE 3 : LONG TERM BORROWINGS		
Loan & Advances from Related parties	69,50,000.00	69,00,000.00
	69,50,000.00	69,00,000.00
NOTE 4 : TRADE PAYABLES		
4.1 SUNDRY CREDITORS :		
For Material Purchase	26,476.00	26,476.00
For Expenses	37,874.00	1,14,987.00
For Liabilities	-	-
For Advance Received From Customer	1,82,843.00	1,78,095.00
	2,47,193.00	3,19,558.00
NOTE 6 : DEFERRED TAXES		
6.1 DEFERRED TAX ASSETS :		
Timing Difference on account of Depreciation	1,214.00	114.00
	1,214.00	114.00
NOTE 7 : LONG TERM LOANS, ADVANCES AND DEPOSITS		
7.1 SECURITY DEPOSITS-UNSECURED CONSIDERED GOODS		
Fixed Deposit With Bank (Including Accrued Interest)	3,25,365.00	3,03,510.00
Deposit With Others	3,000.00	3,000.00
	3,28,365.00	3,06,510.00
NOTE 8 : INVENTORIES		
(At Cost or Market Value whichever is Lower as certified by Directors)		
Material	42,39,276.00	44,38,402.00
	42,39,276.00	44,38,402.00
NOTE 9 : TRADE RECEIVABLES		
SUNDRY DEBTORS UNSECURED CONSIDERED GOODS		
Due for a Period Less than Six Months	33,600.00	81,661.00
Due for a Period Exceeding Six Months	49,508.00	-
	83,108.00	81,661.00
NOTE 10 : OTHER CURRENT ASSETS		
10.1 UNSECURED, CONSIDERED GOODS		
UNLESS OTHERWISE STATED		
Advance Paid to Suppliers	-	10,868.00
GST Credit Balance	10,09,400.00	10,23,699.00
GST Cash Balance	2,685.00	732.00
TDS & TCS	1,976.00	746.00
Preliminary Expense	12,300.00	16,400.00
	10,26,361.00	10,52,445.00
NOTE 11 : CASH AND CASH EQUIVALENTS		
BALANCE WITH BANKS		
With Schedule Bank		
HDFC Bank	20,229.00	20,229.00
ICICI Bank	1,26,819.00	1,29,389.00
Cash on Hand	8,634.00	16,497.00
	1,55,682.00	1,66,115.00



RAYZON BIOCARE PRIVATE LIMITED

SCHEDULE FORMING PART OF THE BALANCE SHEET AS AT 31st MARCH, 2024

NOTE - 5

(All amounts are in Indian ₹)

Particular	Rate (WDV)	Gross Block				Depreciation				Net	
		Total As on 01.04.2023	Addition	Deduction	Total As on 31.03.2024	As on 01.04.2023	For The Year	Deduction	Total As on 31.03.2024	Total As on 31.03.2023	
Computer	63.16%	15,170	-		15,170	2,599	7,940		10,539	12,571	
Printer	63.16%	10,000			10,000	2,872	4,502		7,374	7,128	
Grand Total		25,170	-	-	25,170	5,471	12,442	-	17,913	19,699	
Previous		-	-	-	-	-	-	-	-	-	

Notes :

01. Pursuant to enactment of Companies Act 2013, Effective from April 1, 2015 the company has changed depreciation based upon the useful life of fixed assets as per requirement of Schedule II of the Companies Act 2013. Depreciation is provided on Written Down Value (WDV) method over the estimated useful life of the asset estimated by the management which is equal to the useful life prescribed under schedule II to the Companies Act, 2013.



RAYZON BIOCARE PRIVATE LIMITED

NOTES FORMING PART OF THE STATEMENT OF PROFIT & LOSS A/C AS AT 31st MARCH, 2024

(All amounts are in Indian ₹)

PARTICULARS	AS AT 31.03.2024	AS AT 31.03.2023
NOTE 12 : REVENUE FROM OPERATIONS		
12.1 Sale of Products	2,29,311.00	5,39,950.00
	2,29,311.00	5,39,950.00
NOTE 13 : OTHER INCOME		
13.1 INTEREST INCOME		
FD Interest Income (Accrued)	21,855.00	3,510.00
Interest on Income Tax Refund	24.00	-
	21,879.00	3,510.00
NOTE 14 : PURCHASE OF STOCK IN TRADE		
14.1 PURCHASE (TRADED GOODS)		
Purchase During the Year	-	48,37,672.00
	-	48,37,672.00
NOTE 15 : CHANGES IN INVENTORIES OF TRADED GOODS		
15.1 CLOSING STOCK OF TRADED GOODS		
Traded Goods	42,39,276.00	44,38,402.00
TOTAL CLOSING STOCK	42,39,276.00	44,38,402.00
15.2 OPENING STOCK OF TRADED GOODS		
Traded Goods	44,38,402.00	-
TOTAL OPENING STOCK	44,38,402.00	-
INCREASE(-) / DECREASE IN STOCK	1,99,126.00	(44,38,402.00)
NOTE 16 : EMPLOYEE BENEFIT EXPENSES		
Salary & Bonus	66,300.00	24,600.00
	66,300.00	24,600.00
NOTE 17 : FINANCE COST		
17.1 OTHER EXPENSES		
Bank Charges	136.00	26.00
	136.00	26.00
NOTE 18 : DEPRECIATION AND AMORTISATION EXPENSES		
Depreciation on Tangible Assets	12,442.00	5,471.00
	12,442.00	5,471.00




RAYZON BIOCARE PRIVATE LIMITED

NOTES FORMING PART OF THE STATEMENT OF PROFIT & LOSS A/C AS AT 31st MARCH, 2024

(All amounts are in Indian ₹)

PARTICULARS	AS AT 31.03.2024	AS AT 31.03.2023
NOTE 19 : OTHER EXPENSES		
19.1 DIRECT EXPENSE		
Frieght Charges	5,771.00	1,15,574.00
19.2 ADMINISTRATIVE AND GENERAL EXPENSES		
Printing & Stationery Expense	-	25,310.00
Information Technology Expense	-	15,000.00
Office Expense	13,250.00	11,419.00
Die & Mould Expense	-	1,76,500.00
Travelling & Conveyance Expense	-	2,992.00
Legal Professional Charges	14,331.00	1,06,000.00
Interest on Late Payment of TDS	-	2,421.00
Round Off	(62.00)	1.00
Prilimentary Expense Written Off	4,100.00	4,100.00
19.3 AUDITORS REMUNERATION		
Audit Fees	7,500.00	12,500.00
19.4 SELLING AND DISTRIBUTION EXPENSE		
Commission & Advertising Promotional Expenses	1,30,714.00	9,97,002.00
	1,75,604.00	14,68,819.00
NOTE 20 : TAX EXPENSES		
Current Tax Provision	-	-
Deferred tax	(1,100.00)	(114.00)
	(1,100.00)	(114.00)

As per report of our even date attached
For, P B VANKAWALA & CO.
CHARTERED ACCOUNTANTS.
ICAI FIRM REG. NO 0132418W


(CA. PRASHANT PRAKASH VANKAWALA)
PARTNER

MEMBERSHIP NO : 140231
SURAT : 06 SEPTEMBER, 2024
UDIN : 24140231BKEAPV4087



For and on behalf of the Board
RAYZON BIOCARE PRIVATE LIMITED



DIRECTOR
(GAURAV DHIRUBHAI NAKARANI)
(DIN NO: 08767649)



DIRECTOR
(DARSHIL BHARATBHAI GONDALIYA)
(DIN NO: 08767866)

RAYZON BIOCARE PRIVATE LIMITED

CIN : U24299GJ2021PTC127862

NOTES ON ACCOUNTS FOR THE YEAR ENDED MARCH 31, 2024

Annexure : A : Trade Payables Ageing Schedule

(All amounts are in Indian Rupees (₹).)

as at 31/03/2024

Particulars	Total		
	Less than 1 year	1-2 years	2-3 years
(i) MSME			
Trade Payable			
(ii) Others			
Trade Payable & Expense Payable	8,174.00	56,176.00	
(iii) Disputed dues - MSME			64,350.00
(iv) Disputed dues - Others			
Total	8,174.00	56,176.00	64,350.00



RAYZON BIOCARE PRIVATE LIMITED

CIN : U24299GJ2021PTC127862

NOTES ON ACCOUNTS FOR THE YEAR ENDED MARCH 31, 2024

(All amounts are in Indian Rupees (₹)).

Annexure : B : Trade Receivable Ageing Schedule

as at 31/03/2024

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	
(i) Undisputed Trade receivables - considered good	33,600.00	49,508.00				83,108.00
(ii) Undisputed Trade Receivables - considered doubtful						
(iii) Disputed Trade Receivables considered good						
(iv) Disputed Trade Receivables considered doubtful						
Total	33,600.00	49,508.00	-	-	-	83,108.00

